Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA) and is a drug target of considerable interest for numerous pathologies. We report the expedient, structure-guided evolution of weak physiological allosteric inhibitors (bile salts) into potent competitive Autotaxin inhibitors that do not interact with the catalytic site. Functional data confirms that our lead compound attenuates LPA mediated signaling in cells and reduces LPA synthesis in vivo, providing a promising natural product derived scaffold for drug discovery.
Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators
Posted by
Andrew J. Morris
on 12 09 2020
Related content
12 05 2022
< 1 minute
Coupling stabilizers open KV1-type potassium channels
ABSTRACT: The opening and closing of voltage-gated ion channels are regulated by voltage sensors...
13 11 2021
< 1 minute
Cheminfo Stories 2021 Virtual UGM | JChem in online documents
It has been 13 years since the first customer started to use JChem for Office as an offline,...
13 11 2021
< 1 minute
Cheminfo Stories 2021 Virtual UGM | Editable chemistry in MS Office from online editors
As chemical tools move towards the cloud, more and more browser based chemical editors are...
12 11 2021
< 1 minute
Responding to the Challenge Posed by the Generic Control of Substances
Drug monitoring organizations report that new psychoactive substances continue to emerge, posing...